In vitro and in vivo profile of 5-[(4′-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2-carboxylic acid benzylmethyl carbamoylamide (dirlotapide), a novel …

…, P Bertinato, BH Jaynes, A Hickman, C Miskell…

Index: Li, Jin; Bronk, Brian S.; Dirlam, John P.; Blize, Alan E.; Bertinato, Peter; Jaynes, Burton H.; Hickman, Anne; Miskell, Christine; Pillai, Usha A.; Tibbitts, Jay S.; Haven, Michelle L.; Kolosko, Nicole L.; Barry, Chris J.; Manion, Tara B. Bioorganic and Medicinal Chemistry Letters, 2007 , vol. 17, # 7 p. 1996 - 1999

Full Text: HTML

Citation Number: 16

Abstract

The synthesis of a novel gut selective MTP inhibitor, 5-[(4′-trifluoromethyl-biphenyl-2- carbonyl)-amino]-1H-indole-2-carboxylic acid benzylmethyl carbamoylamide (dirlotapide), and its in vitro and in vivo profile are described. Dirlotapide (3) demonstrated excellent potency against MTP enzyme in HepG2 cells and canine hepatocytes. This novel MTP inhibitor also showed excellent efficacy when tested in a canine food intake model.